What To Know
- This Thailand AI News report highlights how this technology arrives at a critical time when the Thai population is aging rapidly, life expectancy is rising, and demand for specialized medical care is outpacing supply.
- The deployment of the gastroAI-model G in Thailand signals a new era in how AI can be responsibly integrated into national healthcare infrastructures.
Thailand AI News: First AI for Gastric Cancer Diagnosis Approved in Thailand
In a significant stride for digital healthcare in Southeast Asia, Thailand has officially granted medical device approval to Japan-based startup AI Medical Service Inc. (AIM) for its cutting-edge AI-powered diagnostic tool for gastric cancer. The newly approved software, known as “gastroAI-model G,” is designed to assist physicians in identifying cancerous (neoplastic) and non-cancerous (non-neoplastic) lesions in the stomach through advanced image analysis of endoscopic scans.
Thailand becomes the first in Southeast Asia to approve AI-powered software for early gastric cancer detection using endoscopic imaging
Image Credit: AIM
This development marks a historic milestone, as it is the first time that Thailand’s Food and Drug Administration (Thai FDA) has greenlit an artificial intelligence system for diagnosing upper gastrointestinal tract conditions based on lesion differentiation. Given Thailand’s high gastric cancer mortality rate—where approximately 75% of diagnosed individuals succumb to the disease—the tool could dramatically change how early-stage cases are detected. This Thailand AI News report highlights how this technology arrives at a critical time when the Thai population is aging rapidly, life expectancy is rising, and demand for specialized medical care is outpacing supply.
Why Gastric Cancer Needs Early Detection Tools
Gastric cancer is the fifth most common cancer globally, affecting over a million individuals and causing nearly 600,000 deaths annually. Its danger lies in late detection—early-stage stomach cancer is often asymptomatic and difficult to spot, with studies suggesting that up to 25% of early cases are missed during standard endoscopy procedures. When caught in Stage I, the five-year survival rate can be as high as 95%. However, by Stage III or later, this drops to less than 50%, underscoring the life-saving potential of timely diagnosis.
In Thailand, the healthcare system faces the dual challenge of aging demographics and specialist shortages, especially in the field of endoscopy. With a current average life expectancy of 76 years and projections showing population decline in the coming decades, the need for scalable diagnostic solutions is urgent. By importing Japan’s world-class medical imaging technology, AIM’s system could help Thai hospitals and clinics detect gastric cancer more effectively, particularly in underserved regions.
How the gastroAI-model G Works
The gastroAI-model G is a diagnostic support tool that integrates directly with standard endoscopic procedures. Using AI trained on vast datasets of annotated gastric lesion images, the software delivers nearly instantaneous visual feedback to the physician. It classifies lesions into categories—likely neoplastic (adenoma or adenocarcinoma), likely non-neoplastic, or low confidence—along with a visual confidence level and image overlays to guide the endoscopist in real time.
This allows for more accurate and quicker differentiation during procedures, enabling earlier treatment decisions and potentially better patient outcomes. The software was officially registered under Approval Number 68-2-2-2-0006282 by the Thai FDA.
Japan’s Data Powers Global Innovation
Founded on the mission to “Save Lives All Over the World,” AIM leverages Japan’s vast endoscopic data repository to develop AI systems that push the boundaries of cancer diagnostics. Japan is considered a global leader in endoscopy, and AIM aims to transfer this expertise internationally—particularly to regions with growing healthcare demands and limited specialist availability.
The deployment of the gastroAI-model G in Thailand signals a new era in how AI can be responsibly integrated into national healthcare infrastructures. It’s not just a technical achievement but a strategic advancement in closing care gaps and raising diagnostic standards.
With this regulatory approval, AIM’s software could help set a precedent for similar technologies being adopted across Asia, offering hope for earlier detection and fewer deaths from one of the world’s deadliest but most treatable cancers.
The arrival of AI-driven diagnostic tools like gastroAI-model G in Thailand could be a gamechanger. Not only can it assist overburdened clinicians and provide consistent diagnostic quality, but it could also reshape how countries with limited medical resources tackle complex diseases. By merging advanced Japanese technology with Thailand’s urgent healthcare needs, this move represents a powerful model of cross-border medical innovation and collaboration.
For the latest about AI adoption in the Thai Medical Industry, keep on logging to Thailand AI News
